Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by StockNews.com

Analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report issued to clients and investors on Monday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Up 1.3 %

Shares of NAVB stock opened at $0.04 on Monday. The company has a 50 day moving average price of $0.04 and a 200-day moving average price of $0.05. Navidea Biopharmaceuticals has a 52 week low of $0.02 and a 52 week high of $0.28. The firm has a market capitalization of $3.81 million, a PE ratio of -0.63 and a beta of 1.13.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.